TITLE

Multiple drugs

PUB. DATE
November 2017
SOURCE
Reactions Weekly;11/18/2017, Vol. 1678 Issue 1, p131
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article looks at retrospective studies of toxicities developed by patients during concomitant administration or treatment, the treatment received by patients with candesartan cilexetil and amlodipine, and treatment medications discontinued in patients.
ACCESSION #
126306657

 

Related Articles

  • Efficacy and Tolerability of Candesartan Cilexetil and Amlodipine in Patients with Poorly Controlled Essential Hypertension. Nishio, Kazuaki; Kondo, Takeshi; Kobayashi, Youichi // International Journal of Clinical Medicine;May2011, Vol. 2 Issue 2, p64 

    Current treatment guidelines for hypertension in both Europe and the USA stress the importance of aggressive blood pressure control. When monotherapy is not enough to reach treatment targets, there is a need for combination regimens that have both high efficacy and good tolerability. The aim of...

  • Amlodipine Enhances Amelioration of Vascular Insulin Resistance, Oxidative Stress, and Metabolic Disorders by Candesartan in Metabolic Syndrome Rats. Sueta, Daisuke; Nakamura, Taishi; Dong, Yi-Fei; Kataoka, Keiichiro; Koibuchi, Nobutaka; Yamamoto, Eiichiro; Toyama, Kensuke; Yasuda, Osamu; Ogawa, Hisao; Kim-Mitsuyama, Shokei // American Journal of Hypertension;Jun2012, Vol. 25 Issue 6, p704 

    BackgroundThe pharmacological advantage of combination of an angiotensin receptor blocker (ARB) and a calcium-channel blocker (CCB) is not fully defined. This study was undertaken to elucidate the potential benefit of their combination in metabolic syndrome.MethodsSHR/NDmcr-cp (SHRcp), a rat...

  • Candesartan cilexetil.  // Reactions Weekly;6/19/2010, Issue 1306, p13 

    The article describes the case of a male fetus who manifested acute renal failure as well as oligohydramnios upon in utero exposure to candesartan cilexetil.

  • Candesartan more effective in reducing blood pressure. Mayor, Susan // British Journal of Hospital Medicine (17508460);Mar2010, Vol. 71 Issue 3, p129 

    The article reports on the effectiveness of Candesartan, the angiotensin receptor blocker, than losartan in reducing blood pressure in patients with hypertension.

  • Candesartan cilexetil.  // Reactions Weekly;8/28/2010, Issue 1316, p14 

    The article describes the case of a 77-year-old woman with hypertension who developed oral angioedema during treatment with candesartan cilexetil.

  • Erratum in 'Antioxidant Activity-Mediated Neuroprotective Effects of an Antagonist of AT1 Receptors, Candesartan, Against Cerebral Ischemia and Edema in Rats,'. Panahpour, H. // Neurophysiology;Feb2014, Vol. 46 Issue 1, p98 

    A correction to the article "Antioxidant Activity-Mediated Neuroprotective Effects of an Antagonist of AT1 Receptors, Candesartan, against Cerebral Ischemia and Edema in Rats" by H. Panahpour that was published in one of the 2013 issue of the periodical is presented.

  • Candesartan cilexetil.  // Reactions Weekly;8/14/2010, Issue 1314, p14 

    The article describes the case of a male fetus who died of congenital abnormalities caused by in utero exposure to candesartan cilexetil.

  • Candesrtan better than amlodipine hypertension.  // Pulse;4/21/2010, Vol. 70 Issue 13, p10 

    The article focuses on the Candesartan Antihypertensive Survival Evaluaton in Japan (CASE-J) trial which found that candesartan is effective in reducing the risk of new-onset diabetes in patients with hypertension.

  • Candesartan dominates losartan in Sweden.  // PharmacoEconomics & Outcomes News;12/8/2012, Issue 668, p4 

    The article reports on a cost-effectiveness analysis in Sweden that candesartan is more used as a primary preventive treatment of hypertension than losartan due to lower rates of cardiovascular complications.

  • Candesartan Cilexetil. Hoy, Sheridan M.; Keating, Gillian M. // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 5, p335 

    Candesartan cilexetil is the orally administered prodrug of candesartan, an angiotensin II subtype 1 receptor antagonist. The pharmacokinetics (area under the plasma concentration-time curve and maximum plasma concentration) of candesartan do not appear to be affected by age, sex, or weight,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics